

1 **Exclusion tests in Unilateral Primary Aldosteronism**
2 **(EU-PA) Study**

3 **Subtitle: A systematic review and meta-analysis**

4
5 Author names: Rui Zhu, MD, PhD^{1,2*}, Tungalagtamir Shagjaa, MD^{1,3*}, Giacomo
6 Rossitto, MD, PhD^{4,5}, Brasilina Caroccia, PhD⁴, Teresa Maria Seccia, MD, PhD⁴;
7 Dario Gregori, MA, PhD⁶; Gian Paolo Rossi, MD, PhD⁴
8

9 Affiliation:

10 ¹ International PhD Program in Arterial Hypertension and Vascular Biology
11 (ARHYVAB), Department of Medicine – DIMED, University of Padua, Padova, Italy

12 ² Department of Endocrinology, Sichuan Academy of Medical Sciences & Sichuan
13 Provincial People's Hospital, Chengdu, China

14 ³ Department of Neurology, Mongolian National University of Medical Sciences,
15 Ulaanbaatar, Mongolia

16 ⁴ Internal & Emergency Medicine Unit, Department of Medicine – DIMED, University
17 of Padua, Padova, Italy

18 ⁵ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow
19 UK

20 ⁶ Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac,
21 Thoracic and Vascular Sciences and Public Health, University of Padua, Padova, Italy
22

23 ORCID number: 0000-0002-7963-0931 (G. P. Rossi)

24
25 *These authors have equally contributed.
26

27 Correspondence and reprint request:

28 Prof. Gian Paolo Rossi, MD, FACC, FAHA

29 Dipartimento di Medicina -DIMED

30 Unità Complessa di Medicina d'Urgenza e Centro Regionale Specializzato per i
31 disordini della pressione

32 Università di Padova,

33 via Giustiniani, 2, 35122 Padova, Italy.

34 E-mail: gianpaolo.rossi@unipd.it
35

36 **Supplemental Literature Search**

37 **Table S1.** Quantitative Scoring Method for the Assessment of Bias Risk

38 **Table S2.** Excluded studies and criteria for exclusion

39 **Table S3.** Quantitative Scoring for the Quality of Each Single Study

40 **Table S4.** Additional Patients' Characteristics

41 **Table S5.** Meta-regression of the Aldosterone-to-renin Ratio

42 **Table S6.** Meta-regression of the Captopril Challenge Test

43 **Table S7.** Meta-regression of the Saline Infusion Test

44 **Figure S1.** PRISMA Flow Chart

45 **Figure S2.** Mean Average of Quantitative Scoring of the ARR, CCT, and SIT

46 **Figure S3.** Summary Area under the Operating Characteristic Curve of the ARR, CCT,
47 and SIT

48 **Figure S4.** Sensitivity Analysis of the Aldosterone-to-renin Ratio

49 **Figure S5.** Sensitivity Analysis of the Captopril Challenge Test

50 **Figure S6.** Sensitivity Analysis of the Saline Infusion Test

51 **Figure S7.** Funnel Plot Assessing Publication Bias of the ARR, CCT, and SIT

52 **Supplemental Literature Search**

53 Using terms and boolean operators in combination, we conducted a systematic search of relevant articles
54 from PubMed, EMBASE, Web of Science, and Cochrane Library databases on the diagnostic
55 performance of the screening and exclusion tests of human PA published from January 1st, 1970 to
56 December 31st, 2021. The references of published articles were also screened to identify additional
57 relevant studies.

58
59 **PubMed**

60 Search: (((("Hyperaldosteronism"[Mesh]) OR (((((((entry terms: Aldosteronism[Title/Abstract]) OR
61 (Conn Syndrome[Title/Abstract])) OR (Syndrome, Conn[Title/Abstract])) OR (Primary
62 Hyperaldosteronism[Title/Abstract])) OR (Hyperaldosteronism, Primary[Title/Abstract])) OR (Conn's
63 Syndrome[Title/Abstract *][Title/Abstract]) OR predictive value of tests[MeSH Term] OR
64 accuracy*[Title/Abstract])) AND (("1970/01/01"[Date - Publication] : "2021/12/31"[Date - Publication]))

65 Filters: English

66 Items found: 852

67

68 **EMBASE**

No.	Query	Results
#1	'hyperaldosteronism'/exp	15678
#2	'aldosteronism':ab,ti OR 'conn syndrome':ab,ti OR 'syndrome, conn':ab,ti OR 'primary hyperaldosteronism':ab,ti OR 'hyperaldosteronism, primary':ab,ti OR 'conns syndrome':ab,ti	8025
#3	#1 OR #2	16542
#4	'sensitivity and specificity'/exp	418850
#5	'predictive value'/exp	207949
#6	'sensitiv*':ab,ti OR 'accuracy*':ab,ti	2361143
#7	#4 OR #5 OR #6	2583822
#8	#3 AND #7	1635
#9	#3 AND #7 AND [english]/lim AND [1970-2021]/py	1480
#10	#3 AND #7 AND [english]/lim AND [1970-2021]/py AND [humans]/lim	1303

Items found: 1303

69

70 **Web of Science**

# 1	TS= (Hyperaldosteronism or Aldosteronism or Conn Syndrome or Syndrome, Conn or Primary Hyperaldosteronism or Hyperaldosteronism, Primary or Conn's Syndrome or Conns Syndrome or Syndrome, Conn's) Indexes= A&HCI, BKCI-SSH, BKCI-S, CCR- EXPANDED, ESCI, IC, CPCI-SSH, CPCI-S, SCI-EXPANDED	7109
# 2	TS= ((sensitivity and specificity) or predictive value of test or (predictive and value*) or sensitiv* or accuracy*) Indexes= A&HCI, BKCI-SSH, BKCI-S, CCR- EXPANDED, ESCI, IC, CPCI-SSH, CPCI-S, SCI-EXPANDED	3820274
# 3	#1 AND #2 Indexes= A&HCI, BKCI-SSH, BKCI-S, CCR-	854

EXPANDED, ESCI, IC, CPCI-SSH, CPCI-S, SCI-EXPANDED
 # 4 #3 850
 Indexes= A&HCI, BKCI-SSH, BKCI-S, CCR-
 EXPANDED, ESCI, IC, CPCI-SSH, CPCI-S, SCI-EXPANDED
 Timespan=1970-01-01 to 2021-12-31

5 #5 AND #1 818
 Refined by: LANGUAGES: (ENGLISH)
 Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI
 Timespan=1970-01-01 to 2021-12-31

Items found: 818

71

72 **Cochrane Library**

ID	Search	Hits
#1	MeSH descriptor: [Hyperaldosteronism] explode all trees	67
#2	(Aldosteronism):ti,ab,kw OR (Conn Syndrome):ti,ab,kw OR (Syndrome, Conn):ti,ab,kw OR (Primary Hyperaldosteronism):ti,ab,kw OR (Hyperaldosteronism, Primary):ti,ab,kw OR (Conn's Syndrome):ti,ab,kw OR (Conns Syndrome):ti,ab,kw OR (Syndrome, Conn's):ti,ab,kw	157
#3	#1 OR #2	177
#4	MeSH descriptor: [Sensitivity and Specificity] explode all trees	15311
#5	MeSH descriptor: [Predictive Value of Tests] explode all trees	6937
#6	(sensitivity*):ti,ab,kw OR (accuracy*):ti,ab,kw	86299
#7	#4 OR #5 OR #6	91652
#8	#3 AND #7	37
#9	#3 AND #7 with Publication Year from 1970 to 2021, in Trials	37

Items found: 37

73

74 The final literature search was performed on 9th February 2021 (all database, by RZ)

75

76 **Total items found: 3010**

77 **Table S1.** Quantitative Scoring Method for the Assessment of Bias Risk

Domain	Item	Score
Study design & patient selection	1. Were the patients enrolled consecutively or randomly, or not?	0 1 2 3 4 5 6 7 8 9 10
	2. Were the patients pre-selected? e.g. patients with positive and negative ARR, or patients with positive ARR?	0 1 2 3 4 5 6 7 8 9 10
Index test	3. Were the cut-off values of ARR, and/or exclusion tests, pre-specified?	0 1 2 3 4 5 6 7 8 9 10
	4. Were the results interpreted with no knowledge of the final diagnosis?	0 1 2 3 4 5 6 7 8 9 10
Reference standard	5. Was the reference standard used to classify uPA appropriately used?	0 1 2 3 4 5 6 7 8 9 10
	6. Were the results interpreted with no knowledge of the index test?	0 1 2 3 4 5 6 7 8 9 10
Flow & timing	7. Did all patients receive the reference standard?	0 1 2 3 4 5 6 7 8 9 10
	8. Did all patients receive the same reference standard?	0 1 2 3 4 5 6 7 8 9 10
	9. Were some patients excluded from the analysis?	0 1 2 3 4 5 6 7 8 9 10
Total		

78 ARR, aldosterone-to-renin ratio; uPA, unilateral primary aldosteronism.

79 **Table S2.** Excluded studies and criteria for exclusion

Study	Exclusion criteria
Adilijiang, M., 2021(1)	Insufficient data to construct a 2x2 table based on uPA
Ahmed, A., 2014(2)	Duplicate data
Arteaga, E., 1985(3)	Exclusion test for PA subtyping
Berge, C., 2015(4)	Wrong calculation of plasma renin concentration
Burrello, J., 2020(5)	Duplicate data
Castro, O. L., 2002(6)	Insufficient data to construct a 2x2 table based on uPA
Fukumoto, T., 2021(7)	Exclusion test for PA subtyping
Gan, W. J., 2019(8)	Insufficient data to construct a 2x2 table based on uPA
Guo, Z., 2018(9)	Duplicate data
Hashimura, H., 2018(10)	Exclusion test for PA subtyping
Jansen, P. 2014(11)	Insufficient data to construct a 2x2 table based on uPA
Juutilainen, A. M., 2005(12)	Case-control study
Kater, C. E., 2004(13)	Case-control study
Kawashima, J., 2020(14)	Insufficient data to construct a 2x2 table based on uPA
Kidoguchi, S., 2019(15)	Insufficient data to construct a 2x2 table based on uPA
Kline, G. A., 2014(16)	Insufficient data to construct a 2x2 table based on uPA
Kuo, C. C., 2015(17)	Duplicate data
Li, T. Q., 2019(18)	Insufficient data to construct a 2x2 table based on uPA
Li, Y. Y., 2016(19)	Duplicate data
Lin, C., 2020(20)	Duplicate data
Lyons, D. F., 1983(21)	Case-control study
Ma, L. Q., 2018(22)	Duplicate data
Mantero, F., 1990(23)	Exclusion test for PA subtyping
Montori, V. M., 2001(24)	Insufficient data to construct a 2x2 table based on uPA
Muratani, H., 1987(25)	Case-control study
Myśliwiec, J., 2012(26)	Insufficient data to construct a 2x2 table based on uPA
Nagano, H., 2020(27)	Exclusion test for PA subtyping
Nanba, K., 2012(28)	Exclusion test for PA subtyping
Naomi, S., 1987(29)	Case-control study
Pilz, S., 2019(30)	Insufficient data to construct a 2x2 table based on uPA
Rossi, E., 2002(31)	Case-control study
Rossi, G. P., 2007(32)	Duplicate data
Schirpenbach, C., 2006(33)	Case-control study
Streeten, D. H., 1982(34)	Insufficient data to construct a 2x2 table based on uPA
Sun, F., 2021(35)	Exclusion test for PA subtyping
Tamura, N., 2020(36)	Insufficient data to construct a 2x2 table based on uPA
Thuzar, M., 2020(37)	Duplicate data
Wang, K. R., 2020(38)	Insufficient data to construct a 2x2 table based on uPA
Yamashita, K., 2020(39)	Exclusion test for PA subtyping
Zhu, K. Y., 2019(40)	Insufficient data to construct a 2x2 table based on uPA

80 PA, primary aldosteronism; uPA, unilateral primary aldosteronism.

81 **Table S3.** Quantitative Scoring for the Quality of Each Single Study

	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9
ARR									
Bernini 2008	7	8	4	5	6	5	3	3	6
Burrello 2016	6	4	10	5	4	4	4	4	5
Ducher 2012	8	4	8	8	5	3	5	7	6
Fries 2020	9	6	2	6	4	2	3	3	4
Giacchetti 2006	3	4	4	5	3	3	3	3	5
Maiolino 2017a	10	9	9	10	9	7	5	7	6
Maiolino 2017b	10	9	9	10	9	7	5	7	6
Okamoto 2018	9	2	10	5	6	5	4	6	3
Vorselaars 2018	9	7	6	6	1	2	5	2	6
Weickert 2009	2	3	1	5	6	2	2	2	5
CCT									
Kim 2016	5	2	9	5	1	5	4	4	8
Maiolino 2017 ^a	10	10	9	10	10	9	5	7	6
Maiolino 2017 ^b	10	10	9	10	10	9	5	7	6
Meng 2018	3	6	9	7	7	8	3	5	9
Okamoto 2019	9	2	10	5	6	5	4	6	3
Rossi 2007	10	10	9	8	8	9	6	7	7
Song 2018	6	3	8	6	4	7	5	5	7
Wu 2009	7	4	9	7	6	5	3	4	8
Wu 2010	8	4	10	7	8	5	4	3	8
SIT									
Fries 2020	9	6	2	6	4	2	3	3	4

Fuss 2021	7	8	4	5	6	5	3	3	6
Meng 2017	3	6	9	6	7	8	3	5	9
Mulatero 2006	5	2	9	5	2	6	2	2	8
Okamoto 2019	9	2	10	5	6	5	4	6	3
Rossi 2007	10	9	8	9	9	9	7	8	7
Song 2017	6	3	8	6	4	7	5	5	7
Stowasser 2018	4	3	9	7	8	7	5	5	5
Vivien 2019	6	6	8	7	7	5	5	4	5
Zhang 2020	3	5	6	7	2	1	1	1	1
FST									
Okamoto 2019	9	2	10	5	6	5	4	6	3
FUT									
Stowasser 2018	4	3	9	7	8	7	5	5	5

82 ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; SIT, saline infusion test; FST, fludrocortisone suppression test; FUT, furosemide upright test. a and b represent
83 the exploratory and the validation cohort in Maiolino's study, respectively.

84 **Table S4.** Additional Patients' Characteristics

	Setting	Study Design	Wash-out period	Serum K⁺ (mEq/L)	Potassium supplement	Salt intake
Bernini 2008	Single referral center	Retrospective	4w diuretics, 3w others	3.2 (uPA)	Yes	Restricted
Burrello 2016	Single referral center	Prospective	Partly done, 20%	3.6 (PA)	Yes	Liberal
Ducher 2012	Multiple referral centers	Prospective	4w MRA, 2w others, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Liberal
Fries 2020	Multiple referral centers	Prospective	4w MRA/diuretics, 2w others, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Liberal
Fuss 2021	Single referral center	Prospective	4w MRA, > 1w others, only maintain CCB and/or a-blocker	3.7 (uPA)	Yes	Liberal
Giacchetti 2006	Single referral center	Prospective	4w discontinued, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Restricted
Kim 2016	Single referral center	Prospective	6w MRA, 4w others, only maintain CCB and/or a-blocker	3.2 (uPA)	Yes	Liberal
Maiolino 2017 ^a	Multiple referral centers	Prospective	6w MRA, 2w others, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Restricted
Maiolino 2017 ^b	Single referral center	Prospective	4w discontinued, only maintain CCB and/or a-blocker	3.3 (uPA)	Yes	Restricted
Meng 2018	Single referral center	Retrospective	6w MRA, 4w diuretics, 2w others, only maintain CCB and/or a-blocker	2.9 (uPA)	Yes	Liberal
Mulatero 2006	Multiple referral centers	Prospective	8w MRA, 6w diuretic, 3w others, only maintain CCB and/or a-blocker	3.7 (PA)	Yes	Liberal

Okamoto 2019	Single referral center	Prospective	Only maintain CCB and/or a-blocker	3.3 (uPA)	N.A.	Restricted
Rossi 2007	Multiple referral centers	Prospective	6w MRA, 2w others, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Restricted
Song 2018	Single referral center	Prospective	4w MRA, 2w others, only maintain CCB and/or a-blocker	3.2 (PA)	Yes	Restricted
Stowasser 2018	Single referral center	Prospective	6w MRA, 2w others, only maintain CCB and/or a-blocker	3.7 (PA)	N.A.	Liberal
Vivien 2019	Single referral center	Retrospective	6w MRA, 4w diuretics, 2w others, only maintain CCB and/or a-blocker	N.A.	Yes	Liberal
Vorselaars 2018	Single referral center	Prospective	≥ 2w discontinued, only maintain CCB and/or a-blocker	N.A.	Yes	Restricted
Weickert 2009	Single referral center	Prospective	≥ 2w discontinued, only maintain CCB and/or a-blocker	3.3 (uPA)	N.A.	Restricted
Wu 2009	Multiple referral centers	Prospective	2w discontinued, only maintain CCB and/or a-blocker	3.4 (uPA)	Yes	Restricted
Wu 2010	Single referral center	Prospective	3w discontinued, only maintain CCB and/or a-blocker	3.7 (uPA)	Yes	Restricted
Zhang 2020	Single referral center	Prospective	4w MRA/diuretics, 2w others, only maintain CCB and/or a-blocker	4.0 (uPA)	Yes	Liberal

85 CCB, calcium channel blocker; MRA, mineralocorticoid receptor antagonist; N.A., not available; PA, primary aldosteronism; uPA, unilateral primary aldosteronism. a and b
86 represent the exploratory and the validation cohort in Maiolino's study, respectively.

87 **Table S5.** Meta-regression of the Aldosterone-to-renin Ratio

(1)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	9/1	-0.005	2.151	0.998	1.00 (0.00 - 390.56)
Population (suspected PA or positive ARR)	7/3	-2.357	1.829	0.267	0.09 (0.00 - 15.20)
Cutoff (chosen by ROC or not)	5/5	0.898	1.229	0.506	2.45 (0.08 - 74.50)
Reference (golden or gold)	5/5	0.010	1.299	0.994	1.01 (0.03 - 37.21)
(2)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	7/3	-2.369	1.249	0.116	0.09 (0.00 - 2.32)
Cutoff (chosen by ROC or not)	5/5	0.882	1.014	0.425	2.41 (0.18 - 32.76)
Reference (golden or gold)	5/5	0.069	1.185	0.956	1.07 (0.05 - 22.55)
(3)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	7/3	-2.275	0.827	0.033	0.10 (0.01 - 0.78)
Cutoff (chosen by ROC or not)	5/5	0.868	0.972	0.406	2.38 (0.22 - 25.66)
(4)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	7/3	-2.209	0.766	0.024	0.11 (0.02 - 0.67)
(5)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Cutoff (chosen by ROC or not)	5/5	0.722	1.217	0.572	2.06 (0.12 - 36.62)

88 ARR, aldosterone-to-renin ratio; CI, confidence interval; No., number of studies; PA, primary
89 aldosteronism; RDOR, relative diagnostic odds ratio; ROC, receiving operation characteristic curve;
90 Std. Err., standard error.

91 **Table S6.** Meta-regression of the Captopril Challenge Test

(1)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	3/6	-0.151	1.979	0.946	0.86 (0.00 - 4293.95)
Population (suspected PA or positive ARR)	3/6	-0.863	1.591	0.642	0.42 (0.00 - 397.11)
Cutoff (chosen by ROC or not)	2/7	-0.537	2.193	0.829	0.58 (0.00 - 7310.15)
Reference (golden or gold)	3/6	-0.089	1.556	0.960	0.92 (0.00 - 739.01)
Readout variable (ARR or PAC)	6/3	2.405	1.601	0.272	11.07 (0.01 - 10841.02)
(2)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	3/6	-0.217	1.103	0.857	0.80 (0.02 - 26.95)
Population (suspected PA or positive ARR)	3/6	-0.912	1.181	0.496	0.40 (0.01 - 17.21)
Cutoff (chosen by ROC or not)	2/7	-0.506	1.815	0.799	0.60 (0.00 - 194.43)
Readout variable (ARR or PAC)	6/3	2.439	1.283	0.153	11.46 (0.19 - 678.66)
(3)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/6	-0.756	0.751	0.371	0.47 (0.06 - 3.78)
Cutoff (chosen by ROC or not)	2/7	-0.676	1.482	0.672	0.51 (0.01 - 31.18)
Readout variable (ARR or PAC)	6/3	2.430	1.186	0.110	11.36 (0.42 - 305.70)
(4)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/6	-0.911	0.631	0.208	0.4 (0.08 - 2.04)
Readout variable (ARR or PAC)	6/3	2.037	0.771	0.046	7.67 (1.06 - 55.66)
(5)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Readout variable (ARR or PAC)	6/3	2.283	0.779	0.026	9.81 (1.46 - 65.93)
(6)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/6	-1.253	0.801	0.169	0.29 (0.04 - 2.03)


92 ARR, aldosterone-to-renin ratio; CI, confidence interval; No., number of studies; PA, primary
 93 aldosteronism; PAC, plasma aldosterone concentration; RDOR, relative diagnostic odds ratio; ROC,
 94 receiving operation characteristic curve; Std. Err., standard error.

95 **Table S7.** Meta-regression of the Saline Infusion Test

(1)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	6/4	0.647	0.910	0.528	1.91 (0.11 - 34.63)
Population (suspected PA or pos ARR)	3/7	1.349	1.606	0.463	3.85 (0.02 - 639.78)
Cutoff (chosen by ROC or not)	5/5	-0.205	1.429	0.895	0.81 (0.01 - 76.98)
Reference (golden or gold)	3/7	-0.207	1.286	0.883	0.81 (0.01 - 48.75)
Position (seated or recumbent)	5/5	1.459	0.966	0.228	4.30 (0.20 - 93.05)
(2)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	6/4	0.770	0.761	0.369	2.16 (0.26 - 17.84)
Population (suspected PA or positive ARR)	3/7	1.180	1.004	0.305	3.26 (0.20 - 52.88)
Reference (golden or gold)	3/7	-0.190	1.113	0.872	0.83 (0.04 - 18.16)
Position (seated or recumbent)	5/5	1.444	0.723	0.116	4.24 (0.57 - 31.56)
(3)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Continent (Europe or Asia)	6/4	0.904	0.645	0.220	2.47 (0.47 - 12.96)
Population (suspected PA or positive ARR)	3/7	1.048	0.632	0.158	2.85 (0.56 - 14.48)
Position (seated or recumbent)	5/5	1.456	0.573	0.052	4.29 (0.98 - 18.72)
(4)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/7	1.276	0.743	0.137	3.58 (0.58 - 22.05)
Position (seated or recumbent)	5/5	1.440	0.725	0.094	4.22 (0.72 - 24.88)
(5)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Position (seated or recumbent)	5/5	1.082	0.845	0.241	2.95 (0.40 - 21.77)
(6)					
Variable	No.	Coefficient	Std. Err.	p value	RDOR (95% CI)
Population (suspected PA or positive ARR)	3/7	0.837	0.918	0.392	2.31 (0.26 - 20.22)

96 ARR, aldosterone-to-renin ratio; CI, confidence interval; No., number of studies; PA, primary
 97 aldosteronism; RDOR, relative diagnostic odds ratio; ROC, receiving operation characteristic curve;
 98 Std. Err., standard error.

99 **Figure S1. PRISMA Flow Chart**



100

101 ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; FST, fludrocortisone suppression test;


102 FUT, furosemide upright test; PA, primary aldosteronism; PRISMA, The Preferred Reporting Items for

103 Systematic Reviews and Meta-Analyses; SIT, saline infusion test; uPA, unilateral primary aldosteronism.

104 The exploratory and the validation phase indicate studies using the golden and gold standard for the


105 diagnosis of uPA, respectively.

106 **Figure S2.** Mean Average of Quantitative Scoring of the ARR, CCT, and SIT



107 ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; SIT, saline infusion test. a and b represent the exploratory and the validation cohort in Maiolino's study,
 108 respectively.

109 **Figure S3.** Summary Area under the Operating Characteristic Curve of the ARR, CCT, and SIT




110

111 ARR, aldosterone-to-renin ratios; CCT, captopril challenge test; SIT, saline infusion test. Solid diamond: study by the gold standard; empty diamond: study by the golden
112 standard.


113

114 **Figure S4.** Sensitivity Analysis of the Aldosterone-to-renin Ratio




115 Meta-analysis estimates, given named study is omitted. a and b represent the exploratory and the validation cohort in Maiolino's study, respectively.

116 **Figure S5.** Sensitivity Analysis of the Captopril Challenge Test



117 Meta-analysis estimates, given named study is omitted. a and b represent the exploratory and the validation cohort in Maiolino's study, respectively.


118 **Figure S6.** Sensitivity Analysis of the Saline Infusion Test




119 Meta-analysis estimates, given named study is omitted.

120 **Figure S7.** Funnel Plot Assessing Publication Bias of the ARR, CCT, and SIT


A. ARR



B. CCT



C. SIT



121 ARR, aldosterone-to-renin ratio; CCT, captopril challenge test; SIT, saline infusion test.

122 REFERENCES

- 123 1. **Adilijiang M, Luo Q, Wang M, Zhang D, Yao X, Wang G, Zhou K, Li N.**
124 Minor Change of Plasma Renin Activity during the Saline Infusion Test Provide
125 an Auxiliary Diagnostic Value for Primary Aldosteronism. *Int. J. Endocrinol.*
126 2021;2021:5757305.
- 127 2. **Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, Stowasser**
128 **M.** Seated saline suppression testing for the diagnosis of primary aldosteronism:
129 a preliminary study. *J. Clin. Endocrinol. Metab.* 2014;99(8):2745–2753.
- 130 3. **Arteaga E, Klein R, Biglieri EG.** Use of the saline infusion test to diagnose the
131 cause of primary aldosteronism. *Am. J. Med.* 1985;79(0002–9343; 6):722–728.
- 132 4. **Berge C, Courand PY, Harbaoui B, Paget V, Khettab F, Bricca G, Fauvel JP,**
133 **Lantelme P.** Decreased plasma prorenin levels in primary aldosteronism:
134 potential diagnostic implications. *J. Hypertens.* 2015;33(1):118–125.
- 135 5. **Burrello J, Buffolo F, Domenig O, Tetti M, Pecori A, Monticone S, Poglitsch**
136 **M, Mulatero P.** Renin-Angiotensin-Aldosterone System Triple-A Analysis for
137 the Screening of Primary Aldosteronism. *Hypertens. (Dallas, Tex. 1979)*
138 2020;75(1):163–172.
- 139 6. **Castro OL, Yu X, Kem DC.** Diagnostic value of the post-captopril test in
140 primary aldosteronism. *Hypertension* 2002;39:935–938.
- 141 7. **Fukumoto T, Umakoshi H, Ogata M, Yokomoto-Umakoshi M, Matsuda Y,**
142 **Motoya M, Nagata H, Nakano Y, Iwahashi N, Kaneko H, Wada N,**
143 **Miyazawa T, Sakamoto R, Ogawa Y.** Significance of Discordant Results
144 Between Confirmatory Tests in Diagnosis of Primary Aldosteronism. *J. Clin.*
145 *Endocrinol. Metab.* 2021;106(2):E866–E874.
- 146 8. **Gan W, Lin W, Ouyang J, Li Y, Chen D, Yao Z, Feng P.** High efficiency of the
147 aldosterone-to-renin ratio in precisely detecting primary aldosteronism. *J. Hum.*
148 *Hypertens.* 2019;33(1):57–61.
- 149 9. **Guo Z, Poglitsch M, McWhinney BC, Ungerer JPJ, Ahmed AH, Gordon RD,**
150 **Wolley M, Stowasser M.** Aldosterone LC-MS/MS assay-specific threshold
151 values in screening and confirmatory testing for primary aldosteronism. *J. Clin.*
152 *Endocrinol. Metab.* 2018;103(11):3965–3973.
- 153 10. **Hashimura H, Shen J, Fuller PJ, Chee NYN, Doery JCG, Chong W, Choy**
154 **KW, Gwini SM, Yang J.** Saline suppression test parameters may predict
155 bilateral subtypes of primary aldosteronism. *Clin. Endocrinol. (Oxf).*
156 2018;89(3):308–313.
- 157 11. **Jansen PM, Van Den Born BJH, Frenkel WJ, De Bruijne ELE, Deinum J,**
158 **Kerstens MN, Smulders YM, Woittiez AJ, Wijbenga JAM, Zietse R, Danser**
159 **AHJ, Van Den Meiracker AH.** Test characteristics of the aldosterone-to-renin
160 ratio as a screening test for primary aldosteronism. *J. Hypertens.*
161 2014;32(1):115–126.
- 162 12. **Juutilainen AM, Voutilainen ET, Mykkänen L, Niskanen L.** Plasma
163 aldosterone to renin ratio predicts treatment response in primary aldosteronism:
164 is volume loading needed? *Blood Press.* 2005;14(4):245–250.

- 165 13. **Kater CE, Biglieri EG.** The syndromes of low-renin hypertension: “separating
166 the wheat from the chaff.” *Arq. Bras. Endocrinol. Metabol.* 2004;48(5):674–681.
- 167 14. **Kawashima J, Araki E, Naruse M, Kurihara I, Takahashi K, Tamura K,**
168 **Kobayashi H, Okamura S, Miyauchi S, Yamamoto K, Izawa S, Suzuki T,**
169 **Tanabe A.** Baseline plasma aldosterone level and renin activity allowing
170 omission of confirmatory testing in primary aldosteronism. *J. Clin. Endocrinol.*
171 *Metab.* 2020;105(5):dgaa117.
- 172 15. **Kidoguchi S, Sugano N, Hayashi-Ishikawa N, Morisawa N, Tokudome G,**
173 **Yokoo T.** The characteristics of captopril challenge test-positive patients using
174 various criteria. *J. Renin. Angiotensin. Aldosterone. Syst.*
175 2019;20(3):1470320319870891.
- 176 16. **Kline GA, Pasieka JL, Harvey A, So B, Dias VC.** High-probability features of
177 primary aldosteronism may obviate the need for confirmatory testing without
178 increasing false-positive diagnoses. *J. Clin. Hypertens. (Greenwich).*
179 2014;16(7):488–496.
- 180 17. **Kuo CC, Balakrishnan P, Hsein YC, Wu VC, Chueh SCJ, Chen YM, Wu**
181 **KD, Wang MJ, Lin YH, Ho YL, Chang HW, Lin LY, Hu FC, Liu KL, Wang**
182 **SM, Huang KH, Chang CC, Lu CC, Liao SC, Yen RF, Lin WC, Hsieh B Sen.**
183 The value of losartan suppression test in the confirmatory diagnosis of primary
184 aldosteronism in patients over 50 years old. *J. Renin. Angiotensin. Aldosterone.*
185 *Syst.* 2015;16(3):587–598.
- 186 18. **Li T, Ma Y, Zhang Y, Liu Y, Fu T, Zhang R, Kang K, Yang Y, Wang L, Jiang**
187 **Y, Lu Y.** Feasibility of Screening Primary Aldosteronism by Aldosterone-to-
188 Direct Renin Concentration Ratio Derived from Chemiluminescent
189 Immunoassay Measurement: Diagnostic Accuracy and Cutoff Value. *Int. J.*
190 *Hypertens.* 2019;2019:2195796.
- 191 19. **Li Y, Liu Y, Li J, Wang X, Yu Y.** Sodium Infusion Test for Diagnosis of Primary
192 Aldosteronism in Chinese Population. *J. Clin. Endocrinol. Metab.*
193 2016;101(1):89–95.
- 194 20. **Lin C, Yang J, Fuller PJ, Jing H, Song Y, He W, Du Z, Luo T, Cheng Q, Yang**
195 **S, Wang H, Li Q, Hu J, Mei M, Luo S, Liao K, Zhang Y, He Y, He Y, Xiao**
196 **M, Peng B, Goswami R, Zhao C, Feng Z, Li R, Deng H, Liu C, Zhou B, Ren**
197 **W, Long J, Gong L, Peng C, Gao R, Xiao X.** A combination of captopril
198 challenge test after saline infusion test improves diagnostic accuracy for primary
199 aldosteronism. *Clin. Endocrinol. (Oxf).* 2020;92(2):131–137.
- 200 21. **Lyons DF, Kem DC, Brown RD, Hanson CS, Carollo ML.** Single dose
201 captopril as a diagnostic test for primary aldosteronism. *J. Clin. Endocrinol.*
202 *Metab.* 1983;57(0021–972; 5):892–896.
- 203 22. **Ma L, Song Y, Mei M, He W, Hu J, Cheng Q, Tang Z, Luo T, Wang Y, Zhen**
204 **Q, Wang Z, Qing H, He Y, Li Q, Yang S.** Age-Related Cutoffs of Plasma
205 Aldosterone/Renin Concentration for Primary Aldosteronism Screening. *Int. J.*
206 *Endocrinol.* 2018;2018. doi:10.1155/2018/8647026.
- 207 23. **Mantero F, Armanini D, Biason A, Boscaro M, Carpena G, Fallo F, Opocher**
208 **G, Rocco S, Scaroni C, Sonino N.** New aspects of mineralocorticoid

- hypertension. *Horm. Res.* 1990;34:175–180.
- 209
210 24. **Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST.**
211 Validity of the aldosterone-renin ratio used to screen for primary aldosteronism.
212 *Mayo Clin. Proc.* 2001;76(9):877–882.
- 213 25. **Muratani H, Abe I, Tomita Y, Ueno M, Takishita S, Kawazoe N, Tsuchihashi**
214 **T, Kawasaki T, Fujishima M.** Single oral administration of captopril may not
215 bring an improvement in screening of primary aldosteronism. *Clin. Exp.*
216 *Hypertens. A.* 1987;9(2–3):611–614.
- 217 26. **Myśliwiec J, Łukowski Z, Grodzka A, Pilaszewicz A, Drągowski S, Górska**
218 **M.** Diagnostics of primary aldosteronism: is obligatory use of confirmatory tests
219 justified? *J. Renin. Angiotensin. Aldosterone. Syst.* 2012;13(3):367–371.
- 220 27. **Nagano H, Kono T, Saiga A, Kubota Y, Fujimoto M, Felizola SJA, Ishiwata**
221 **K, Tamura A, Higuchi S, Sakuma I, Hashimoto N, Suzuki S, Koide H,**
222 **Takehita N, Sakamoto S, Ban T, Yokote K, Nakamura Y, Ichikawa T, Uno**
223 **T, Tanaka T.** Aldosterone Reduction Rate After Saline Infusion Test May Be a
224 Novel Prediction in Patients With Primary Aldosteronism. *J. Clin. Endocrinol.*
225 *Metab.* 2020;105(3):dgz092.
- 226 28. **Nanba K, Tamanaha T, Nakao K, Kawashima ST, Usui T, Tagami T, Okuno**
227 **H, Shimatsu A, Suzuki T, Naruse M.** Confirmatory Testing in Primary
228 Aldosteronism. *J. Clin. Endocrinol. Metab.* 2012;97(5):1688–1694.
- 229 29. **Naomi S, Umeda T, Iwaoka T, Sato T.** Effects of sodium intake on the captopril
230 test for primary aldosteronism. *Jpn. Heart J.* 1987;28(3):357–365.
- 231 30. **Pilz S, Keppel MH, Trummer C, Theiler-Schwetz V, Pandis M, Borzan V,**
232 **Pittrof M, Obermayer-Pietsch B, Grübler MR, Verheyen N, Stepan V,**
233 **Meinitzer A, Voelkl J, März W, Tomaschitz A.** Diagnostic Accuracy of the
234 Aldosterone-to-Active Renin Ratio for Detecting Primary Aldosteronism. *J.*
235 *Endocr. Soc.* 2019;3(9):1748–1758.
- 236 31. **Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F.** High prevalence
237 of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio
238 as a screening test among Italian hypertensives. *Am. J. Hypertens.* 2002;15(10
239 Pt 1):896–902.
- 240 32. **Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G,**
241 **Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo**
242 **G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero**
243 **F.** Prospective evaluation of the saline infusion test for excluding primary
244 aldosteronism due to aldosterone-producing adenoma. *J. Hypertens.*
245 2007;25:1433–1442.
- 246 33. **Schirpenbach C, Seiler L, Maser-Gluth C, Rudiger F, Nickel C, Beuschlein**
247 **F, Reincke M.** Confirmatory testing in normokalaemic primary aldosteronism:
248 the value of the saline infusion test and urinary aldosterone metabolites. *Eur. J.*
249 *Endocrinol.* 2006;154(0804–4643; 6):865–873.
- 250 34. **Streeten DHP, Anderson GH.** Simplified screening procedures for primary
251 aldosteronism. Studies on the mechanism of the hyper-responsiveness to
252 furosemide and standing. *Clin. Exp. Hypertens. A.* 1982;4(9–10):1663–1676.

- 253 35. **Sun F, Hong Y, Zhang H, Liu X, Zhao Z, He H, Yan Z, Zhu Z.** Determination
254 of adrenal hypersecretion in primary Aldosteronism without aldosterone-
255 production adenomas. *BMC Endocr. Disord.* 2021;21(1):114.
- 256 36. **Tamura N, Yamada K, Hatakeyama H, Torii-Hanakita M, Kyo C, Kosugi R,**
257 **Yonemoto T, Ogawa T, Kotani M, Usui T, Inoue T.** Parameters of captopril
258 challenge test can predict results of other confirmatory tests for primary
259 aldosteronism and propose the next test to be done. *Endocr. J.* 2020;67(7):741–
260 750.
- 261 37. **Thuzar M, Young K, Ahmed AH, Ward G, Wolley M, Guo Z, Gordon RD,**
262 **Mcwhinney BC, Ungerer JP, Stowasser M.** Diagnosis of Primary
263 Aldosteronism by Seated Saline Suppression Test -Variability Between
264 Immunoassay and HPLC-MS/MS. *J. Clin. Endocrinol. Metab.*
265 2020;105(3):dgz150.
- 266 38. **Wang K, Hu J, Yang J, Song Y, Fuller PJ, Hashimura H, He W, Feng Z,**
267 **Cheng Q, Du Z, Wang Z, Ma L, Yang S, Li Q.** Development and Validation of
268 Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism.
269 *J. Clin. Endocrinol. Metab.* 2020;105(7):2449–2456.
- 270 39. **Yamashita K, Yatabe M, Seki Y, Bokuda K, Watanabe D, Shimizu S,**
271 **Morimoto S, Ichihara A.** Comparison of the shortened and standard saline
272 infusion tests for primary aldosteronism diagnostics. *Hypertens. Res.*
273 2020;43(10):1113–1121.
- 274 40. **Zhu KY, Zhang Y, Zhang WJ, Li HY, Feng WH, Zhu DL, Li P.** The captopril
275 challenge test for diagnosing primary Aldosteronism in a Chinese population.
276 *BMC Endocr. Disord.* 2019;19(1):65.
277